4-Trifluoromethoxyphenylboronic acid

We are 4-Trifluoromethoxyphenylboronic acid CAS:139301-27-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 4-Trifluoromethoxyphenylboronic acid
Other Name:
4-Trifluoromethoxyphenylboronic acid
(4-(Trifluoromethoxy)phenyl)boronic acid
4-(Trifluoromethoxy)benzeneboronic Acid
4-(Trifluoromethoxy)phenylboronic Acid
CAS No: 139301-27-2
MF: C7H6BF3O3
MW: 205.92700
Density: 1.41 g/cm3
Boiling point: 256.6ºC at 760 mmHg
Melting point: 123-127 °C(lit.)
Flash point: 109ºC
Refractive index: 1.461
UN Number: Not dangerous goods.
UN Proper Shipping Name: Not dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: White to beige crystalline powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Applicationd as Sonidegib intermediate, pharmaceutical intermediate, pesticide intermediate, OLED intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

4-Trifluoromethoxyphenylboronic acid


Related News: API and raw material are often confused due to the similar usage of the two terms.4-Biphenylboronic acid The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.N- (3-trimetoxisililpropil) anilina CAS:3068-76-6 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.Acetyl ketene The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.

Related Products
Product Name
CYCLOBUTANECARBOXAMIDE View Details
tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate View Details
1,2-Dibromoethane View Details
3-[3-(trifluoromethyl)phenyl]propanal manufacturer 2,4-Difluorotoluene manufacturer Dibenzo[b,e]oxepin-11(6H)-one manufacturer Propyl isocyanate manufacturer 5-Bromo-2-Hydroxy-3-Picoline manufacturer